Skip to main content
SpringerLink
Log in
Book cover

Diminished Ovarian Reserve and Assisted Reproductive Technologies pp 157–174Cite as

Minimal Stimulation Protocol for Assisted Reproductive Technologies in Women with Diminished Ovarian Reserve and/or Advanced Reproductive Age

  • Chapter
  • First Online:

  • 604 Accesses

Abstract

We present the minimal stimulation protocol for assisted reproductive technologies (ART) that we recommend for women with diminished ovarian reserve and/or advanced reproductive age. The protocol is individualized for each patient reflecting the heterogeneity of this patient population. The minimal stimulation requires assuring the follicle synchronization while keeping LH unsuppressed. Daily clomiphene citrate and, in some cases, daily letrozole are used throughout the entirety of the stimulation. Highly purified human menopausal gonadotropin is added on day 5 of stimulation to be used at 150 IU every other day. Close monitoring allows individualization of half-dose gonadotropin antagonist administration to prevent premature luteinizing hormone surge. This protocol is aimed at accumulating frozen embryos for elective frozen-thawed embryo transfer. Minimal stimulation for ART requires specific conditions and many allocated resources.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod. 2006;21(2):352–7.

    Article  CAS  Google Scholar 

  2. Pinkas H, Sapir O, Avrech OM, Ben-Haroush A, Ashkenzi J, Fisch B, et al. The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome. J Assist Reprod Genet. 2008;25(1):29–33.

    Article  Google Scholar 

  3. Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril. 2013;99(5):1305–10.

    Article  CAS  Google Scholar 

  4. Chang EM, Han JE, Won HJ, Kim YS, Yoon TK, Lee WS. Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization. J Assist Reprod Genet. 2012;29(3):225–30.

    Article  Google Scholar 

  5. Fisch JD, Keskintepe L, Sher G. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure. Fertil Steril. 2008;89(2):342–7.

    Article  CAS  Google Scholar 

  6. Frattarelli JL, Hill MJ, McWilliams GD, Miller KA, Bergh PA, Scott RT Jr. A luteal estradiol protocol for expected poor-responders improves embryo number and quality. Fertil Steril. 2008;89(5):1118–22.

    Article  CAS  Google Scholar 

  7. Hill MJ, McWilliams GD, Miller KA, Scott RT Jr, Frattarelli JL. A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates. Fertil Steril. 2009;91(3):739–43.

    Article  CAS  Google Scholar 

  8. Lee H, Choi HJ, Yang KM, Kim MJ, Cha SH, Yi HJ. Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization. Obstet Gynecol Sci. 2018;61(1):102–10.

    Article  Google Scholar 

  9. Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertil Steril. 2003;79(2):316–21.

    Article  Google Scholar 

  10. Fanchin R, Cunha-Filho JS, Schonauer LM, Righini C, de Ziegler D, Frydman R. Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulating hormone and inhibin B levels and ovarian follicular status. Fertil Steril. 2003;79(3):585–9.

    Article  Google Scholar 

  11. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod. 2003;18(12):2698–703.

    Article  CAS  Google Scholar 

  12. Teramoto S. Clomiphene citrate for IVF. In: Chavez-Badiola A, Allahbadia GN, editors. Textbook of minimal stimulation IVF – milder, mildest or back to nature. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2011. p. 37–43.

    Chapter  Google Scholar 

  13. Marut EL, Williams RF, Cowan BD, Lynch A, Lerner SP, Hodgen GD. Pulsatile pituitary gonadotropin secretion during maturation of the dominant follicle in monkeys: estrogen positive feedback enhances the biological activity of LH. Endocrinology. 1981;109(6):2270–2.

    Article  CAS  Google Scholar 

  14. Quyyumi SA, Pinkerton JV, Evans WS, Veldhuis JD. Estradiol amplifies the amount of luteinizing hormone (LH) secreted in response to increasing doses of gonadotropin-releasing hormone by specifically augmenting the duration of evoked LH secretory events and hence their mass. J Clin Endocrinol Metab. 1993;76(3):594–600.

    CAS  PubMed  Google Scholar 

  15. Urban RJ, Veldhuis JD, Dufau ML. Estrogen regulates the gonadotropin-releasing hormone-stimulated secretion of biologically active luteinizing hormone. J Clin Endocrinol Metab. 1991;72(3):660–8.

    Article  CAS  Google Scholar 

  16. Veldhuis JD, Beitins IZ, Johnson ML, Serabian MA, Dufau ML. Biologically active luteinizing hormone is secreted in episodic pulsations that vary in relation to stage of the menstrual cycle. J Clin Endocrinol Metab. 1984;58(6):1050–8.

    Article  CAS  Google Scholar 

  17. Veldhuis JD, Rogol AD, Perez-Palacios G, Stumpf P, Kitchin JD, Dufau ML. Endogenous opiates participate in the regulation of pulsatile luteinizing hormone release in an unopposed estrogen milieu: studies in estrogen-replaced, gonadectomized patients with testicular feminization. J Clin Endocrinol Metab. 1985;61(4):790–3.

    Article  CAS  Google Scholar 

  18. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update. 1996;2(6):483–506.

    Article  CAS  Google Scholar 

  19. Ghobadi C, Mirhosseini N, Shiran MR, Moghadamnia A, Lennard MS, Ledger WL, et al. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol. 2009;49(2):147–54.

    Article  CAS  Google Scholar 

  20. Ernst S, Hite G, Cantrell JS, Richardson A Jr, Benson HD. Stereochemistry of geometric isomers of clomiphene: a correction of the literature and a reexamination of structure-activity relationships. J Pharm Sci. 1976;65(1):148–50.

    Article  CAS  Google Scholar 

  21. Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril. 1986;46(3):392–6.

    Article  CAS  Google Scholar 

  22. Young SL, Opsahl MS, Fritz MA. Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. Fertil Steril. 1999;71(4):639–44.

    Article  CAS  Google Scholar 

  23. Messinis IE, Templeton A. Blockage of the positive feedback effect of oestradiol during prolonged administration of clomiphene citrate to normal women. Clin Endocrinol (Oxf). 1988;29(5):509–16.

    Article  CAS  Google Scholar 

  24. Teramoto S, Kato O. Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study. Reprod Biomed Online. 2007;15(2):134–48.

    Article  CAS  Google Scholar 

  25. Kolibianakis EM, Zikopoulos K, Schiettecatte J, Smitz J, Tournaye H, Camus M, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19(11):2490–6.

    Article  CAS  Google Scholar 

  26. Orvieto R, Meltcer S, Liberty G, Rabinson J, Anteby EY, Nahum R. Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue? Gynecol Endocrinol. 2012;28(6):422–4.

    Article  CAS  Google Scholar 

  27. Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. 2014;12:17.

    Article  Google Scholar 

  28. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril. 2012;97(5):1108–14.e1.

    Article  CAS  Google Scholar 

  29. Mak SM, Wong WY, Chung HS, Chung PW, Kong GW, Li TC, et al. Effect of mid-follicular phase recombinant LH versus urinary HCG supplementation in poor ovarian responders undergoing IVF – a prospective double-blinded randomized study. Reprod Biomed Online. 2017;34(3):258–66.

    Article  CAS  Google Scholar 

  30. Wolfenson C, Groisman J, Couto AS, Hedenfalk M, Cortvrindt RG, Smitz JE, et al. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online. 2005;10(4):442–54.

    Article  CAS  Google Scholar 

  31. Thuesen LL, Loft A, Egeberg AN, Smitz J, Petersen JH. Andersen AN. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod. 2012;27(10):3074–84.

    Article  CAS  Google Scholar 

  32. Choi J, Smitz J. Luteinizing hormone and human chorionic gonadotropin: origins of difference. Mol Cell Endocrinol. 2014;383(1–2):203–13.

    Article  CAS  Google Scholar 

  33. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 1998;13(11):3023–31.

    Google Scholar 

  34. Bukulmez O, Rehman KS, Langley M, Carr BR, Nackley AC, Doody KM, et al. Precycle administration of GnRH antagonist and microdose HCG decreases clinical pregnancy rates without affecting embryo quality and blastulation. Reprod Biomed Online. 2006;13(4):465–75.

    Article  CAS  Google Scholar 

  35. Winkler N, Bukulmez O, Hardy DB, Carr BR. Gonadotropin releasing hormone antagonists suppress aromatase and anti-Mullerian hormone expression in human granulosa cells. Fertil Steril. 2010;94(5):1832–9.

    Article  CAS  Google Scholar 

  36. Tan O, Carr BR, Beshay VE, Bukulmez O. The extrapituitary effects of GnRH antagonists and their potential clinical implications: a narrated review. Reprod Sci. 2013;20(1):16–25.

    Article  Google Scholar 

  37. Wu YG, Barad DH, Kushnir VA, Wang Q, Zhang L, Darmon SK, et al. With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization. J Ovarian Res. 2018;11(1):23.

    Article  Google Scholar 

  38. Wu YG, Barad DH, Kushnir VA, Lazzaroni E, Wang Q, Albertini DF, et al. Aging-related premature luteinization of granulosa cells is avoided by early oocyte retrieval. J Endocrinol. 2015;226(3):167–80.

    Article  CAS  Google Scholar 

  39. Roque M, Sampaio M, Geber S. Follicular flushing during oocyte retrieval: a systematic review and meta-analysis. J Assist Reprod Genet. 2012;29(11):1249–54.

    Article  Google Scholar 

  40. Georgiou EX, Melo P, Brown J, Granne IE. Follicular flushing during oocyte retrieval in assisted reproductive techniques. Cochrane Database Syst Rev. 2018;(4):CD004634.

    Google Scholar 

  41. Mendez Lozano DH, Brum Scheffer J, Frydman N, Fay S, Fanchin R, Frydman R. Optimal reproductive competence of oocytes retrieved through follicular flushing in minimal stimulation IVF. Reprod Biomed Online. 2008;16(1):119–23.

    Article  Google Scholar 

  42. Babayev SN, Park CW, Bukulmez O. Intracytoplasmic sperm injection indications: how rigorous? Semin Reprod Med. 2014;32(4):283–90.

    Article  Google Scholar 

  43. Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril. 2002;77(4):776–80.

    Article  Google Scholar 

  44. Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril. 2005;84(Suppl 1):S95.

    Article  Google Scholar 

  45. ACOG Practice Bulletin No. 194: polycystic ovary syndrome. Obstet Gynecol 2018;131(6):e157–e171.

    Google Scholar 

  46. Ozmen B, Sonmezer M, Atabekoglu CS, Olmus H. Use of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocols. Reprod Biomed Online. 2009;19(4):478–85.

    Article  CAS  Google Scholar 

  47. Yarali H, Esinler I, Polat M, Bozdag G, Tiras B. Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol. Fertil Steril. 2009;92(1):231–5.

    Article  CAS  Google Scholar 

  48. Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev. 2017;(11):CD008528.

    Google Scholar 

  49. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril. 2004;82(6):1561–3.

    Article  CAS  Google Scholar 

  50. Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med. 2015;373(13):1230–40.

    Article  CAS  Google Scholar 

  51. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.

    Article  CAS  Google Scholar 

  52. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885–90.

    Article  CAS  Google Scholar 

  53. Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online. 2013;26(4):337–44.

    Article  CAS  Google Scholar 

  54. Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci. 2015;30(3):290–5.

    Article  CAS  Google Scholar 

  55. Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29(11):993–6.

    Article  CAS  Google Scholar 

  56. Shapira M, Raanani H, Meirow D. IVF for fertility preservation in breast cancer patients--efficacy and safety issues. J Assist Reprod Genet. 2015;32(8):1171–8.

    Article  CAS  Google Scholar 

  57. Rose BI, Laky DC, Rose SD. A comparison of the use of clomiphene citrate and letrozole in patients undergoing IVF with the objective of producing only one or two embryos. Facts Views Vis Obgyn. 2015;7(2):119–26.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Reproductive Endocrinology and Infertility, Fertility and Advanced Reproductive Medicine Assisted Reproductive Technologies Program, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Orhan Bukulmez

Authors
  1. Orhan Bukulmez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Orhan Bukulmez .

Editor information

Editors and Affiliations

  1. Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    Orhan Bukulmez

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bukulmez, O. (2020). Minimal Stimulation Protocol for Assisted Reproductive Technologies in Women with Diminished Ovarian Reserve and/or Advanced Reproductive Age. In: Bukulmez, O. (eds) Diminished Ovarian Reserve and Assisted Reproductive Technologies. Springer, Cham. https://doi.org/10.1007/978-3-030-23235-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-23235-1_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-23234-4

  • Online ISBN: 978-3-030-23235-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation